Moving forward in clinical research with master protocols.
Contemp Clin Trials
; 106: 106438, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1230388
ABSTRACT
With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Clinical Protocols
/
Clinical Trials as Topic
/
Biomedical Research
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Contemp Clin Trials
Journal subject:
Medicine
/
Therapeutics
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS